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The History and Diagnosis of 
Behçet’s Disease
Müzeyyen Gönül, Arzu Kılıç and Bilgen Gençler
Abstract
Behçet’s disease (BD) is a multisystemic vasculitis of unknown aetiology, 
initially reported by Turkish dermatologist Hulusi Behçet in 1937. Hulusi Behçet 
presented the disease as a triple symptom complex with recurrent aphthosis, genital 
ulceration and recurrent hypopyon uveitis. But subsequent studies have shown that 
it can affect many organs with wide clinical spectrum. It is challenging to make 
a definite diagnosis because there is no pathognomic laboratory test to diagnose 
Behçet’s disease. The diagnosis is based on variable group of clinical manifestations. 
Many new diagnostic/classification criteria have been developed through the years. 
International Study Group (ISG) Criteria and the International Criteria for Behçet’s 
Disease (ICBD) are the most commonly acceptable criteria for the diagnosis of 
BD. However, due to the broad clinical spectrum of Behçet’s disease, there will 
always be Behçet’s patients who do not complete the criteria. Therefore, the experi-
ence of the physician and evaluation of the findings with a good clinical anamnesis 
is of great importance in the diagnosis.
Keywords: Hulusi Behçet, Behçet’s disease, International Study Group criteria, 
International Criteria for Behçet’s disease
1. Introduction
Behçet’s disease (BD) is a multisystemic vasculitis according to the 2012 Revised 
International Chapel Hill Consensus Conference Nomenclature of Vasculitides [1]. 
The autoimmune process, which is triggered by the environmental and infectious 
factors on the basis of the genetic factors, is held responsible for the formation of 
the disease [2]. The definition of the disease dates back to ancient times until the 
time of Hippocrates [3]. However, for the first time in modern medicine in 1937, 
Prof. Dr. Hulusi Behçet described it as a separate entity consisting of oral aphthosis, 
genital ulceration, and iridocyclitis with hypopyon [4].
2.  Hulusi Behçet: a life dedicated to dermatology (the person behind the 
eponym)
Hulusi Behçet was born on 20 February 1889 in Istanbul. Hulusi Behçet was 
raised by his grandmother after his mother’s death when he was young and he had a 
difficult childhood. He settled in Damascus because of his father’s work. He studied 
at a French school and learned French, Latin, and German. In 1906, he started 
Kuleli Military Medical School when he was only 16 years old and graduated in 1910. 
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After his specialization training on skin and venereal diseases in Gulhane Military 
Hospital, he worked in Edirne Military hospital for 4 years. Afterwards, he went 
to Europe and worked in Budapest and Berlin for a short time and returned to his 
country. He worked as a freelance doctor for a while, and then he worked at Haskoy 
Venereal Diseases Hospital and Guraba Hospital after that in 1933; he became the 
head of the Department of Skin and Venereal Diseases of Istanbul University and 
continued this position until 1947 [5, 6].
He is interested in many different areas of dermatology such as syphilis, leish-
maniasis, dermatitis Figus carcia, parasitosis, and mycosis, but he is mostly known 
for his studies on Behçet’s disease, which is named after him. He presented his 
research in many national and international meetings and congresses and published 
126 articles between 1921 and 1940 [5, 6].
Studies on Behçet’s disease began with a patient he first saw in 1924.The patient 
had recurrent hypopyon uveitis accompanied by ulcerations in the mouth and scro-
tum, painful nodules on the legs, fever, and joint pain and was variously diagnosed 
in Istanbul and Vienna and was followed by Hulusi Behçet later on for many more 
years [5–7].
In 1930, he conducted a study on a female patient with recurrent ocular 
symptoms and oral and genital lesions and in 1936 on a male patient with oral 
pemphigus-like wounds, acneiform lesions on the back, scrotal ulcer, night fever, 
abdominal pain, and ocular symptoms [5–7].
As a result of his research on these three patients, Hulusi Behçet first suggested 
in 1937 that recurrent oral aphthous lesions, genital ulceration, and recurrent 
hypopyon uveitis were the symptoms of a single disease as a triple symptom com-
plex [4]. He wrote this view in 1937 in the journal Dermatologische Wochenschrift and 
presented it to his colleagues at a congress in France in the same year. At the same 
congress, it was suggested that viruses may play a role in the etiology of this condi-
tion, especially those of dental origin [5, 6, 8] (Figure 1).
Figure 1. 
Hulusi Behçet MD (1889–1948).
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In 1938, Dermatologische Wohenschrift published his thoughts in more detail. In 
the following years, new case reports came from different countries. While ophthal-
mologists accepted this new disease, dermatologists believed it to be a symptom of 
another existing skin disease. However, as a result of the new articles published in 
different parts of the world, the disease was accepted to be a separate entity. At the 
international medical congress in Geneva, with the suggestion of Prof. Mischner 
from Zurich Medical Faculty, this newly diagnosed disease was called “Morbus 
Behçet” [5, 6].
In 1930, Dr. Benedictos Adamantiades (1875–1962), a Greek ophthalmolo-
gist, reported a patient with recurrent hypopyonic irritation accompanied 
by mucocutaneous lesions and arthritis [9]. In later years, he wrote new case 
reports, but he did not interpret this as a triple complex; focusing only on the 
eye, he suggested that hypopyonic iridocyclitis was a separate clinical disease 
by itself [10–12]. Undoubtedly, although his colleagues from many parts of the 
world contributed to the acceptance of Behçet’s disease as a separate clinical 
entity, the first person to describe the triple triad and to present it to the world 
through his articles and presentations is our esteemed professor, doctor Hulusi 
Behçet.
3. The diagnosis and classification criteria of Behçet’s disease
Firstly, although Behçet’s disease is accepted as a triple symptom complex with 
recurrent aphthosis, genital ulceration, and recurrent hypopyon uveitis, subsequent 
studies have shown that it is a multisystemic chronic inflammatory disease that can 
affect many organs [1, 13].
There is no pathognomic laboratory test to diagnose Behçet’s disease. The 
disease’s wide clinical spectrum, its showing ethnical and geographical differences, 
and the differences that it shows in the time of onset of symptoms and its courses 
with different findings in each patient are the factors that make it difficult to diag-
nose. Therefore, the experience of the physician and evaluation of the findings with 
a good clinical anamnesis is of great importance in the diagnosis [14].
Although it is a relatively young disease, many different diagnostic/classification 
criteria have been developed. The first one was created by Curth in 1946 [15]. In 
1969, Hewitt et al. presented the diagnostic criteria and revised and reformed them 
in 1971 [16, 17]. Many new diagnostic criteria have been established in the light of 
the studies that have been carried out until today. The main ones are Mason and 
Barnes in 1969, Japan criteria in 1972, Hubault and Hamza in 1974, O’Duffy in 1974, 
Chen in 1980, Dilsen et al. in 1986, Japan revised criteria in 1988, International 
Study Group (ISG) in 1990, Iran in 1993, Classification Tree in 1993, Dilsen revised 
in 2000, Korea in 2003, the International Criteria for Behçet’s Disease (ICBD) in 
2006, and the revised ICBD in 2014 [18–32].
The Japan Research Committee for Behçet’s Disease created the Japanese criteria 
in 1972. There are four major symptoms according to these criteria: oral aphthosis, 
genital aphthosis, skin lesions, and ocular findings. In the presence of an ocular 
lesion, one different major finding is sufficient for the diagnosis. If there are no 
ocular findings, the presence of the other three major findings is essential for the 
diagnosis. It is called “complete form” if there are four major findings, and it is 
called “incomplete form” if there are fewer findings [19]. Japan criteria were revised 
in 1988. Five minor findings were added to the major findings, and two minor 
findings were suggested to replace one missing major finding. These minor findings 
include arthritis/arthralgia, gastrointestinal manifestations, vascular thrombosis, 
neurological manifestations, and epididymitis [24].
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In the Fourth International Conference on Behçet’s Disease, which was held in 
London in 1985, it was planned to establish a diagnostic criterion with high sensitiv-
ity and specificity. Therefore, the International Behçet’s Disease Study Group was 
established [25, 33]. In 7 countries (France, Iran, Japan, Tunisia, Turkey, the UK, 
and the USA) and in 12 separate institutions, 912 Behçet patients together with 308 
control patients were included in a study and followed up. Twenty-eight patients 
without oral ulceration were excluded from the study [25]. In the light of the data 
obtained, “International Behçet’s Disease Study Group Classification Criteria” was 
established and published in 1990. ISG classification criteria consist of five items. 
The first criterion is recurrent oral ulceration at least three times a year and is a 
sine qua non. The other four criteria consist of recurrent genital ulceration, eye 
lesions (anterior uveitis, posterior uveitis, retinal vasculitis), skin lesions (erythema 
nodosum, pseudofolliculitis, or papulopustular lesions), and positive pathergy test. 
In addition to the major criterion oral aphthosis, the existence of two of the four 
findings is enough for the diagnosis of Behçet’s disease [25, 34] (Table 1).
The sensitivity and specificity of ISG classification criteria were found to be 
92 and 97%, respectively [25]. Although it is one of the most widely used criteria 
to date, several concerns about its sensitivity have arisen. In fact, many studies 
have been performed that measure the performance of diagnostic/classification 
criteria for Behçet’s disease. Because of the high specificity of ISG, the risk of 
another disease being misdiagnosed and classified as BD is very low. However, 
many Behçet’s disease patients go undiagnosed due to its low sensitivity [35]. 
Another controversial issue is that oral aphthosis is an indispensable finding in 
ISG, but it has been shown that oral aphthosis may not be in 1–10% of BD patients 
[36]. Behçet patients with severe, specific symptoms such as vascular involvement 
can also go without diagnosis with these criteria, and thus the concern of delay in 
treatment has arisen [37, 38].
In 1993, Iran presented the ISG criteria in an international conference by modi-
fying them to overcome the problem of low sensitivity and low accuracy. According 
to these criteria, it consisted of five items similar to ISG, but oral aphthosis was not 
mandatory. Oral aphthosis was given 2 points, and other lesions were given 1 point, 
and 3 points were sufficient to diagnose BD [26].
In 1993, Iran released a new classification system, using the Classification and 
Regression Tree method, called the classification tree. The presence of one of the 
five subgroups in the patient alone is sufficient to diagnose BD. These subgroups are 
as follows: oral aphthosis + genital aphthosis, oral aphthosis + skin lesions + positive 
Recurrent oral 
ulceration
Minor or major aphthous ulceration or herpetiform ulceration observed by 
physician or patient (at least three occurrences within a 12-month period)
Plus any two of the following criteria
Recurrent genital 
ulceration
Aphthous ulceration or scarring observed by the physician or patient
Eye lesions Anterior uveitis, posterior uveitis, or cells in vitreous on slit-lamp examination or 
retinal vasculitis detected by an ophthalmologist
Skin lesions Erythema nodosum observed by physician or patient, pseudofolliculitis, or 
papulopustular lesions or acneiform nodules observed by the physician in 
postadolescent patients (not receiving corticosteroid treatment)
Positive pathergy test Read by physician at 24–48 hours.
*Findings applicable only in the absence of other clinical explanations.
Table 1. 
International study group (ISG) criteria for the diagnosis of Behçet’s disease.
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pathergy test, oral aphthosis + ocular findings, genital aphthosis + ocular findings, 
and positive pathergy test + ocular findings [27].
In 2000, the original criteria were revised by Dilsen, suggesting that three of the 
six diagnostic criteria were sufficient to diagnose BD. These criteria are oral aphtho-
sis, genital ulceration, skin lesions (pseudofolliculitis, erythema nodosum), ocular 
findings, thrombophlebitis, and positive pathergy test [28].
In 2003, Korea established its own diagnostic criterion for BD. This criterion 
contains six items: oral aphthosis, genital ulceration, skin lesions, ocular findings, 
positive pathergy test, and gastrointestinal involvement. Three points and above is 
sufficient to diagnose BD with three points for genital ulceration and one point for 
other findings [29].
In 2003 the First International Workshop of Behçet’s Disease was held in Austria. 
In this workshop, it was decided that a team of eight countries would prepare a 
proposal to develop the ISG criteria and to establish new criteria for Behçet’s disease 
if necessary [35].
In the 11th International Conference on Behçet’s Disease in Antalya (Turkey) in 
2004, the International Team for the Revision of the ISG criteria was created which 
was composed of clinicians from 27 countries. Among these countries, in the first place 
comes Turkey, and the rest were Austria, Azerbaijan, China, Egypt, France, Germany, 
Greece, India, Iran, Iraq, Israel, Italy, Japan, Jordan, Libya, Morocco, Pakistan,  
Portugal, Russia, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, Tunisia, and  
the USA.
Between January 2005 and June 2006, 2556 BD and 1163 control patients were 
included in a study who were selected by expert opinion, rather than a classifica-
tion system. The International Criteria for Behçet’s Disease included a new scor-
ing system for the diagnosis of Behçet’s disease. It consisted of six items: genital 
ulceration and ocular findings with 2 points and oral aphthosis, skin lesions, 
vascular lesions, and pathergy test with 1 point. A score of 3 or more was suf-
ficient for the diagnosis of BD. In 2010, ICBD criteria were revised and presented 
at the 14th International Conference on Behçet’s Disease in London. In 2014, these 
criteria were published in the Journal of the European Academy of Dermatology and 
Venereology. The differences from the classical form were the addition of neurolog-
ical findings as 1 point and the increase of oral aphthosis to 2 points. Pathergy test 
was optional but 1 point should be added at its presence. Four points and above 
was sufficient for the diagnosis of Behçet’s disease. The sensitivity and specificity 
of ICBD was 94.8 and 90.5%, respectively [30–32] (Table 2).
Sign/symptom points
Oral aphthosis 2
Genital ulceration 2
Ocular lesions 2
Skin lesions 1
Vascular manifestations 1
Neurological manifestations 1
Positive pathergy test* 1
*1-Pathergy test is optional. However, when it is performed, one extra point may be assigned for a positive result.
2-A patient scoring 4 points or above was classified as having Behçet’s disease.
Table 2. 
The international criteria for Behçet’s disease (ICBD)—point-score system.
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4. Differential diagnosis of Behçet’s disease
Since Behçet’s disease has a broad clinical spectrum, many diseases are included 
in the differential diagnosis. Although many diagnostic criteria have been devel-
oped, it can still be difficult to diagnose Behçet’s disease, and it may be necessary to 
exclude diseases that show similar findings in the differential diagnosis.
4.1 Differential diagnosis of mucocutaneous findings
4.1.1 Oral aphthosis
Recurrent aphthous stomatitis (RAS), viral infections such as herpes simplex 
virus and Coxsackievirus infections, nutritional deficiencies such as vitamin B 
and iron, recurrent erythema multiform, oral erosive lichen planus, autoimmune 
bullous diseases, fixed drug eruption, Stevens-Johnson syndrome, toxic epidermal 
necrolysis, inflammatory bowel diseases (IBD), Reiter syndrome, systemic lupus 
erythematosus, celiac disease, mouth and genital ulcers with inflamed cartilage 
(MAGIC) syndrome, must be Periodic Fever, Aphthous Stomatitis, Pharyngitis, 
Adenitis (PFAPA) syndrome, hematologic malignancies, and trauma [39–42].
4.1.2 Genital ulceration
Herpes simplex infection; erosive lichen planus; autoimmune bullous derma-
toses; sexually transmitted infectious diseases, especially syphilis; and fixed drug 
eruption [41, 43].
4.1.3 Skin lesions
Papulopustular lesions can be confused with acne and bacterial folliculitis [14, 44].
4.2 Differential diagnosis of systemic findings
The diseases of the similar systemic findings with BD are inflammatory bowel 
diseases, seronegative arthropathies, sarcoidosis, lupus erythematosus and other 
systemic vasculitis, multiple sclerosis as neurological involvement, and stroke of the 
young adult [14, 45].
Differential diagnosis of BD from IBD may be challenging for clinicians 
because findings of both two diseases include gastrointestinal manifestations, 
fever, oral aphthosis, pyoderma gangrenosum, erythema nodosum, Sweet syn-
drome like dermatosis, neutrophilic lobular panniculitis, ocular involvement, 
arthritis, vasculitis, and thrombotic events. Moreover, the manifestations of 
intestinal BD are similar to IBD. There are no diagnostic laboratory tests or endo-
scopic findings for the differential diagnosis of both diseases. Endoscopic find-
ings of Behçet’s disease demonstrate single or few, large, round, or oval-shaped 
ulcerations. Longitudinal ulcers in a discontinuous distribution and cobblestone 
appearance are endoscopic features of IBD. However, neurologic involvement is 
not observed in IBD [46–50].
Bowel-associated dermatosis-arthritis syndrome (BADAS) is a recurrent 
neutrophilic dermatosis which is associated with bowel bypass surgery and gas-
trointestinal disorders like IBD and diverticulitis [51, 52]. The syndrome should 
be distinguished from BD, due to the similar findings such as oral aphthosis, 
vesiculopustular dermatosis, erythema nodosum, neutrophilic lobular panniculitis, 
fever, vasculitis, and arthritis. The other cutaneous findings of BD and ocular and 
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neurologic involvement are not expected findings for BADAS. The pathergy test is 
also negative in the BADAS patients [50].
Although many criteria have been developed for the diagnosis of Behçet’s 
disease, there are still a number of difficulties to establish a definitive diagnosis and 
for making differential diagnosis. Therefore, newly defined molecular markers and 
universal criteria with high sensitivity and specificity are needed.
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